Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nathanson

Showing results (241-250 of 528) with videos related to

Pageof 53
Sort By:
JAMA Network Open|August 5, 2025
Racial Differences in Screening Eligibility by Breast Density After State-Level Insurance ExpansionMattia A Mahmoud, Sarah Ehsan, Sara P Ginzberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinicHelen A Shih, Fergus J Couch, Katherine L Nathanson, et al.
Cancer Research|August 27, 2009
Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688delArcangela De Nicolo, Emilio Parisini, Quan Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibMelissa A Wilson, Fengmin Zhao, Richard Letrero, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
A Thiopurine-like Mutagenic Process Defines TGCT SubtypesKevin M Brown, Jun Zhong, Adriana Morales Miranda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2017
Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer RiskAnita Villani, Mary-Louise C Greer, Jennifer M Kalish, et al.
Plos One|March 26, 2013
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingBrijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, et al.
JAMA Network Open|December 15, 2025
Genomic Ascertainment of CHEK2-Related Cancer PredispositionSun Young Kim, Jung Kim, Mark Ramos, et al.
JCO Oncology Practice|July 18, 2024
Integration of Germline Genetic Testing Into Routine Clinical Practice for Patients With Pancreatic AdenocarcinomaKelsey S Lau-Min, Heather Symecko, Kelsey Spielman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex TestingJudith Balmaña, Laura Digiovanni, Pragna Gaddam, et al.
Pageof 53

Showing results (241-250 of 528) with videos related to

Sort By:
Pageof 53
JAMA Network Open|August 5, 2025
Racial Differences in Screening Eligibility by Breast Density After State-Level Insurance ExpansionMattia A Mahmoud, Sarah Ehsan, Sara P Ginzberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinicHelen A Shih, Fergus J Couch, Katherine L Nathanson, et al.
Cancer Research|August 27, 2009
Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688delArcangela De Nicolo, Emilio Parisini, Quan Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibMelissa A Wilson, Fengmin Zhao, Richard Letrero, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
A Thiopurine-like Mutagenic Process Defines TGCT SubtypesKevin M Brown, Jun Zhong, Adriana Morales Miranda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2017
Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer RiskAnita Villani, Mary-Louise C Greer, Jennifer M Kalish, et al.
Plos One|March 26, 2013
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingBrijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, et al.
JAMA Network Open|December 15, 2025
Genomic Ascertainment of CHEK2-Related Cancer PredispositionSun Young Kim, Jung Kim, Mark Ramos, et al.
JCO Oncology Practice|July 18, 2024
Integration of Germline Genetic Testing Into Routine Clinical Practice for Patients With Pancreatic AdenocarcinomaKelsey S Lau-Min, Heather Symecko, Kelsey Spielman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex TestingJudith Balmaña, Laura Digiovanni, Pragna Gaddam, et al.
Pageof 53